Aggribloc Injection
Tirofiban
5mg
Abbott India Ltd.
| Pack size | |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 5510.64 NPR |
Indications
Aggribloc Injection is used for:
Acute coronary syndrome
Adult Dose
Intravenous
Acute coronary syndrome
Adult: In combination w/ unfractioned heparin and oral antiplatelet therapy, including aspirin: Patients w/ ST-elevation MI (STEMI) undergoing primary PCI or patients w/ non-ST-elevation MI (NSTEMI) undergoing PCI w/in 4 hr of diagnosis: Initially, 25 mcg/kg bolus over 3 min followed by a continuous infusion of 0.15 mcg/kg/min for 12-24 hr.
Max duration: 48 hr. Patients w/ NSTEMI undergoing PCI >4 hr after diagnosis: Initially, 0.4 mcg/kg/min for 30 min followed by 0.1 mcg/kg/min, started at the time of diagnosis and continued for at least 48 hr. Infusion may be continued during coronary angiography and maintained for 12-24 hr after angioplasty or atherectomy. Max duration: 108 hr.
Hepatic impairment: Severe: Contraindicated.
Child Dose
Renal Dose
Renal impairment:
CrCl (ml/min) Dosage Recommendation
<30 Reduce dose by 50%.
Administration
Contra Indications
History of thrombocytopenia during earlier use of GP IIb/IIIa receptor antagonist; history of stroke w/in 30 days or history of haemorrhagic stroke; history of intracranial disease (e.g. neoplasm, aneurysm); active or recent (w/in 30 days) clinically relevant bleeding (e.g. GI bleeding); malignant HTN; relevant trauma or major surgery (w/in the past 6 wk); thrombocytopenia (platelet count <100,000/mm3), disorders of platelet function; clotting disturbances. Severe hepatic failure.
Precautions
Patient w/ anaemia, active peptic ulcer (w/in the past 3 mth), uncontrolled HTN, acute pericarditis, active or history of vasculitis, suspected aortic dissection, haemorrhagic retinopathy, occult blood in stool or haematuria, thrombocytopenia (platelet count <150,000/mm3) or known history of platelet function disturbance, recent bleeding (<1 yr), severe CHF, cardiogenic shock. Severe trauma or surgery (>6 wk but <3 mth previously); traumatic or protracted CPR, organ biopsy or lithotripsy (w/in the past 2 wk), puncture of a non-compressible vessel (w/in 24 hr), recent epidural procedure. Renal and mild to moderate hepatic impairment. Pregnancy and lactation. Monitoring Parameters Monitor signs of bleeding, platelet counts, activated thromboplastin time (aPTT), haematocrit and Hb before and periodically (e.g. w/in the first 6 hr of the loading infusion and daily thereafter).
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Tirofiban :
Nausea, headache, fever, rashes and other hypersensitivity reactions, thrombocytopenia, anaemia, minor bleeding (e.g. mild mucocutaneous bleeding).
Potentially Fatal: Major bleeding (e.g. intracranial or retroperitoneal haemorrhage).
Mechanism of Action
Tirofiban is a non-peptide tyrosine derivative that prevents fibrinogen binding to the glycoprotein (GP) IIb/IIIa receptor, leading to inhibition of platelet function, evidenced by its ability to inhibit ex vivo ADP-induced platelet aggregation and prolong bleeding time.
Note
Aggribloc 5mg Injection manufactured by Abbott India Ltd.. Its generic name is Tirofiban. Aggribloc is availble in Nepal.
Farmaco Nepal drug index information on Aggribloc Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.